3 results
The objective of this pilot study is to demonstrate that NAVA ventilation is superior compared to pressure support and pressure control ventilation in work of breathing (expressed as pressure-time product) patient ventilator synchrony and other…
The objectives of this are to establish the safety, tolerability, and efficacy of VRDN-001, and the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of VRDN-001 in HV and TED patients over a dose range of 3.0 to 20.0 mg/kg.
Primairy objective: Validating of nerve fiber length, nerve fiber density, nerve fiber branches and tortuosity of a healthy control group, sarcoidosis patients with small fiber neuroapthy and sarcoidosis patients without small fiber neuropathy.…